Release Date: December 23, 2016
Expiration Date: December 31, 2018
- CE for this activity will not be available after this date.
Reference Number: 16022076
A post impact survey invitation will be sent to all learners who complete this activity (see below). Participation is completely optional.
Overview: Initial and subsequent findings from the Women’s Health Initiative (WHI) resulted in confusion regarding the safety and efficacy of menopause hormone therapy (MHT). Additional studies and reanalysis of the WHI findings over the past 14 years have brought management of menopausal symptoms back to the forefront in women’s health. This interactive activity is designed to update primary care and women’s health providers on the most current evidence-based practices in managing menopausal symptoms and evaluating individualized benefits vs risks of patients based on personal and family history. A review of the WHI will be included as well as an examination of FDA and off-label MHT pharmacologic therapeutic options. Other topics included non pharmacologic symptom management choices and non-hormonal agents that are guideline-based for women who either don’t want to take hormonal agents or who cannot take MHT.
After completing this activity, the learner will be better able to:
- Identify key conclusions of the preliminary and subsequent findings of the WHI as reported by the Principal Investigators of the study.
- Describe reporting components from the WHI conclusions that factored into misinterpretations into the analysis of risks and benefits associated with use of hormone therapy in postmenopausal women.
- Discuss the short- and long-term consequences to menopausal women, especially in younger women who are likely to be more symptomatic, if clinicians do not explore the severity of menopausal transition in their aging female patients.
- Discuss evidence-based hormone therapy guidelines issued from renowned health organizations for treatment and management of various symptoms and comorbidities associated with menopausal transition.
- Apply risk benefits to the clinical case studies presented to determine best practice decisions in recommending pharmacological vs non-pharmacological therapeutic options for management of menopausal transition.
Judith Berg, PhD, RN, WHNP-BC, FAAN, FAANP
Terri Suresh-DeNeui, RN, MSN, ACNP, DNPs
This activity was planned in accordance with AANP Accreditation Standards and Policies and is supported by an unrestricted educational grant from Pfizer. Dr. Berg and Terry Suresh-DeNeui have no relevant relationships to disclose.
This educational activity may contain opinions of the speaker from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
AANP CE Credit: To complete the CE for this activity, review all the content, successfully complete on the online post-test and submit the online program evaluation.
Post Impact Survey
Between 30 to 90 days after this activity is completed, AANP will send out an invitation to participate in a Post Impact Outcomes Survey (PI Survey) . Participation in the survey is optional and does not affect the credit earned. The PI surveys help measure the overall impact of the education content, see how the material impacts practice behaviors and what changes are being made. This anonymous information is crucial in helping the Education department improve current activities as well as guiding AANP in planning future CE activities.
For questions about this online CE activity, or more information concerning the AANP CE Center, please contact the AANP CE Center Manager at CECenter@aanp.org.